A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

NCT06107803 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Negative Symptoms in Schizophrenia

Interventions

DRUG: Roluperidone 64 mg
DRUG: Olanzapine 10 MG

Sponsor

Minerva Neurosciences